EMA Backs Wegovy Oral Pill, Reigniting Novo Nordisk Valuation Debate

The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a positive opinion on the oral pill formulation of Wegovy, Novo Nordisk’s blockbuster obesity treatment. The regulatory nod has drawn renewed attention to the company’s pipeline—particularly among investors monitoring the fast-growing obesity and cardiovascular therapy markets.

The development comes at a pivotal moment for Novo Nordisk. While the stock has rebounded sharply over the short term—gaining 11.18% in the past 30 days and 18.61% over the past 90 days—the longer-term picture remains mixed. Year-to-date returns are still down 12.49%, and total shareholder return over the past year has declined by 34.31%. That suggests the recent rally is starting to repair some damage after a prolonged stretch of weakness for long-term holders.

Obesity treatments have become one of the most competitive segments in global pharma, with demand projected to surge as regulators and healthcare systems confront rising chronic-disease burdens. Wegovy’s oral pill, if approved by the European Commission, could offer a more convenient alternative to its injectable counterpart and potentially expand the patient population. That scenario has fueled speculation about Novo Nordisk’s revenue trajectory well into the next decade.

Against this backdrop, analysts have been reassessing the company’s valuation. Using a widely cited fair-value model, Novo Nordisk’s equity is pegged at approximately DKK851.04 per share—a stark contrast to the recent closing price of DKK289. The gap implies that the market has not fully priced in the long-term potential of the company’s obesity portfolio and broader metabolic drug pipeline.

Yet the path to that higher valuation hinges on several assumptions: accelerated revenue growth, sustained margins, and a richer earnings multiple. Any deviation—whether from regulatory delays, pricing pressure in the diabetes and obesity segment, or broader market headwinds—could temper those expectations. The company’s earnings have recently beaten forecasts, but investors should remain cautious about the risks that come with high-growth narratives in a sector prone to policy shifts and competitive disruption.

For those weighing the opportunity, the key is to separate the headline optimism from the underlying fundamentals. With mixed signals on both risk and reward, the decision ultimately rests on a close reading of the data, including the three primary growth catalysts and four notable warning signs that analysts have flagged.

This analysis is based on publicly available data and analyst forecasts. It does not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. The author and the publisher may hold positions in the securities mentioned.